Acuitas Therapeutics
Acuitas Therapeutics is a Vancouver-based biotechnology company focused on enabling nucleic acid therapeutics through lipid nanoparticle (LNP) delivery systems. The company provides LNP research, formulation, analytical, preclinical and process-development capabilities to partners, and supports translation from preclinical optimization to clinical trials, regulatory submissions and manufacturing scale-up.
Industries
Nr. of Employees
small (1-50)
Acuitas Therapeutics
Vancouver, British Columbia, Canada, North America
Patents
Products
Acuitas LNP Delivery Technology
Proprietary lipid nanoparticle (LNP) delivery platform enabling new classes of medicines based on nucleic acids, supported by comprehensive research, chemistry, formulation development, and analytical capabilities.
Acuitas LNP Delivery Technology
Proprietary lipid nanoparticle (LNP) delivery platform enabling new classes of medicines based on nucleic acids, supported by comprehensive research, chemistry, formulation development, and analytical capabilities.
Services
Technology evaluation assessment and licensing of LNP delivery systems and access to proprietary lipid materials for partner development programs.
Development of LNP formulations and analytical method development and testing to characterize product quality, payload loading and stability.
Design and execution of pharmacology, biodistribution and safety studies, including non-human primate studies, to support clinical translation.
Development of scalable manufacturing processes and coordination of technology transfer to contract manufacturers for clinical and commercial supply.
Provision and management of cGMP-grade lipid materials to support partner clinical programs.
Ongoing project coordination, partner onboarding and cross-team collaboration to manage multi-disciplinary development programs.
Technology evaluation assessment and licensing of LNP delivery systems and access to proprietary lipid materials for partner development programs.
Development of LNP formulations and analytical method development and testing to characterize product quality, payload loading and stability.
Design and execution of pharmacology, biodistribution and safety studies, including non-human primate studies, to support clinical translation.
Development of scalable manufacturing processes and coordination of technology transfer to contract manufacturers for clinical and commercial supply.
Provision and management of cGMP-grade lipid materials to support partner clinical programs.
Ongoing project coordination, partner onboarding and cross-team collaboration to manage multi-disciplinary development programs.
Expertise Areas
- Lipid nanoparticle delivery systems
- Ionizable lipid chemistry and materials development
- Formulation development for nucleic acid therapeutics
- Analytical method development for complex biologics
Key Technologies
- Lipid nanoparticle (LNP) delivery systems
- Ionizable lipid synthesis and SAR modeling
- PEGylated lipid stabilization
- mRNA, siRNA and guide RNA delivery
News & Updates
Poster presentations on mRNA-LNP base editing spatial resolution and PK/distribution of mRNA-LNP in gonadal tissues at ASGCT 2024.
Company presentations and data releases on next-generation LNP at industry conferences.
Multiple peer-reviewed publications in 2024–2025 reporting LNP-enabled vaccine and gene-editing research outcomes.
LNP formulations developed by the company have been used in clinically approved nucleic acid products.
Multiple organizational awards including national and regional industry recognitions between 2021 and 2024.
Poster presentations on mRNA-LNP base editing spatial resolution and PK/distribution of mRNA-LNP in gonadal tissues at ASGCT 2024.
Company presentations and data releases on next-generation LNP at industry conferences.
Multiple peer-reviewed publications in 2024–2025 reporting LNP-enabled vaccine and gene-editing research outcomes.
LNP formulations developed by the company have been used in clinically approved nucleic acid products.
Multiple organizational awards including national and regional industry recognitions between 2021 and 2024.